Immuneering CorporationIMRXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +6.08% | +20.97% | +21.36% | +32.93% | +41.74% |
| Weighted Average Shares Diluted Growth | +6.08% | +20.97% | +21.36% | +32.93% | +41.74% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -48.61% | -42.40% | -48.04% | +251.61% | +340.08% |
| Book Value per Share Growth | -56.93% | -56.06% | -64.04% | +197.11% | +272.45% |
| Debt Growth | -6.72% | -6.81% | -7.22% | -7.66% | -8.13% |
| R&D Expense Growth | +24.85% | +2.40% | -1.86% | -3.95% | -37.05% |
| SG&A Expenses Growth | -15.90% | -2.67% | +0.99% | +11.77% | +25.71% |